Ugo Testa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1389614/publications.pdf

Version: 2024-02-01

260 papers	13,256 citations	20817 60 h-index	29157 104 g-index
261 all docs	261 docs citations	261 times ranked	16501 citing authors

#	Article	IF	Citations
1	Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling. Expert Review of Molecular Diagnostics, 2022, 22, 77-100.	3.1	13
2	Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment. Cancers, 2022, 14, 2565.	3.7	12
3	New promising developments for potential therapeutic applications of high-dose ascorbate as an anticancer drug. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 179-191.	0.9	3
4	Precision Medicine Treatment in Acute Myeloid Leukemia Is Not a Dream. Hemato, 2021, 2, 131-153.	0.6	3
5	Genetic Alterations of Metastatic Colorectal Cancer. Biomedicines, 2020, 8, 414.	3.2	27
6	Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. Medicines (Basel, Switzerland), 2020, 7, 44.	1.4	13
7	Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias. Cancers, 2020, 12, 2427.	3.7	13
8	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Medical Sciences (Basel, Switzerland), 2020, 8, 18.	2.9	72
9	Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells. Frontiers in Oncology, 2020, 10, 621458.	2.8	29
10	Endothelial Progenitors in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1263, 85-115.	1.6	10
11	Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines (Basel, Switzerland), 2019, 6, 82.	1.4	68
12	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. Leukemia Research, 2019, 84, 106191.	0.8	5
13	CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers, 2019, 11, 1358.	3.7	98
14	Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. Cancers, 2019, 11, 260.	3.7	28
15	The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. Haematologica, 2019, 104, 973-985.	3.5	31
16	Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy. OncoTargets and Therapy, 2018, Volume 11, 131-155.	2.0	45
17	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 2018, 51, 1700745.	6.7	136
18	Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation. Blood Cells, Molecules, and Diseases, 2018, 69, 57-64.	1.4	58

#	Article	IF	Citations
19	High Doses of Vitamin C and Leukemia: In Vitro Update. , 2018, , .		1
20	Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors. Medical Sciences (Basel, Switzerland), 2018, 6, 85.	2.9	9
21	Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers, 2018, 10, 248.	3.7	258
22	Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. Medical Sciences (Basel, Switzerland), 2018, 6, 31.	2.9	167
23	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines (Basel, Switzerland), 2018, 5, 16.	1.4	123
24	Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. Medical Sciences (Basel, Switzerland), 2017, 5, 28.	2.9	22
25	Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers, 2017, 9, 127.	3.7	112
26	Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution. Medicines (Basel, Switzerland), 2017, 4, 67.	1.4	67
27	miR-146 and miR-155: Two Key Modulators of Immune Response and Tumor Development. Non-coding RNA, 2017, 3, 22.	2.6	169
28	Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Biomedicines, 2017, 5, 65.	3.2	81
29	The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia. Oncotarget, 2017, 8, 84074-84085.	1.8	4
30	High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro. Oncotarget, 2017, 8, 32550-32565.	1.8	47
31	IL-3 Receptor Alpha Chain is a Biomarker and a Therapeutic Target of Myeloid Neoplasms. Journal of Molecular Biomarkers & Diagnosis, 2016, 07, .	0.4	2
32	Endothelial progenitor cells in hematologic malignancies. Stem Cell Investigation, 2016, 3, 26-26.	3.0	16
33	Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives. International Journal of Hematologic Oncology, 2016, 5, 143-164.	1.6	6
34	Oxidative stress and hypoxia in normal and leukemic stem cells. Experimental Hematology, 2016, 44, 540-560.	0.4	89
35	PML-RAR alpha induces the downmodulation of HHEX: a key event responsible for the induction of an angiogenetic response. Journal of Hematology and Oncology, 2016, 9, 33.	17.0	5
36	Conditioned medium from human umbilical vein endothelial cells markedly improves the proliferation and differentiation of circulating endothelial progenitors. Blood Cells, Molecules, and Diseases, 2016, 61, 58-65.	1.4	14

#	Article	IF	Citations
37	Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Annals of Hematology, 2016, 95, 673-680.	1.8	68
38	Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy. Haematologica, 2015, 100, 1160-1171.	3.5	20
39	Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells. PLoS ONE, 2015, 10, e0126968.	2.5	17
40	MicroRNAs expressed in hematopoietic stem/progenitor cells are deregulated in acute myeloid leukemias. Leukemia and Lymphoma, 2015, 56, 1466-1474.	1.3	8
41	miR-21 is overexpressed in NPM1-mutant acute myeloid leukemias. Leukemia Research, 2015, 39, 221-228.	0.8	27
42	Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells, Molecules, and Diseases, 2015, 55, 336-346.	1.4	32
43	Experimental and investigational therapies for chemotherapy-induced anemia. Expert Opinion on Investigational Drugs, 2015, 24, 1433-1445.	4.1	9
44	Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines. Annals of Hematology, 2015, 94, 1807-1816.	1.8	31
45	A miRNA Signature in Human Cord Blood Stem and Progenitor Cells as Potential Biomarker of Specific Acute Myeloid Leukemia Subtypes. Journal of Cellular Physiology, 2015, 230, 1770-1780.	4.1	33
46	Human cord blood-derived hemogenic endothelium generates mast cells. Blood Cells, Molecules, and Diseases, 2015, 54, 195-197.	1.4	0
47	SCF-mediated Î³-globin gene expression in adult human erythroid cells is associated with KLF1, BCL11A and SOX6 down-regulation. Blood Cells, Molecules, and Diseases, 2015, 54, 1-3.	1.4	2
48	Targeting of leukemia-initiating cells in acute promyelocytic leukemia. Stem Cell Investigation, 2015, 2, 8.	3.0	16
49	Salinomycin Potentiates the Cytotoxic Effects of TRAIL on Glioblastoma Cell Lines. PLoS ONE, 2014, 9, e94438.	2.5	33
50	Endothelial progenitors. Blood Cells, Molecules, and Diseases, 2014, 52, 186-194.	1.4	33
51	CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomarker Research, 2014, 2, 4.	6.8	202
52	Transcriptional fine-tuning of microRNA-223 levels directs lineage choice of human hematopoietic progenitors. Cell Death and Differentiation, 2014, 21, 290-301.	11.2	57
53	miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. Oncogene, 2013, 32, 3648-3654.	5.9	60
54	The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias. Leukemia Research and Treatment, 2013, 2013, 1-14.	2.0	9

#	Article	IF	Citations
55	MicroRNA-486-3p Regulates Î³-Globin Expression in Human Erythroid Cells by Directly Modulating BCL11A. PLoS ONE, 2013, 8, e60436.	2.5	102
56	Human umbilical cord is a unique and safe source of various types of stem cells suitable for treatment of hematological diseases and for regenerative medicine. Blood Cells, Molecules, and Diseases, 2012, 49, 20-28.	1.4	33
57	The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer. Journal of Hematology and Oncology, 2012, 5, 13.	17.0	191
58	A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells. PLoS ONE, 2012, 7, e35073.	2.5	41
59	Autocrine Role of Angiopoietins during Megakaryocytic Differentiation. PLoS ONE, 2012, 7, e39796.	2.5	19
60	Human Haemato-Endothelial Precursors: Cord Blood CD34+ Cells Produce Haemogenic Endothelium. PLoS ONE, 2012, 7, e51109.	2.5	23
61	Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations. British Journal of Haematology, 2011, 153, 33-42.	2.5	21
62	Leukemia stem cells. Annals of Hematology, 2011, 90, 245-271.	1.8	46
63	CDDO-Im is a stimulator of megakaryocytic differentiation. Leukemia Research, 2011, 35, 534-544.	0.8	6
64	MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias. Blood Cancer Journal, 2011, 1, e26-e26.	6.2	50
65	Mechanism of human Hb switching: a possible role of the kit receptor/miR 221-222 complex. Haematologica, 2010, 95, 1253-1260.	3.5	45
66	Transcriptional silencing of the ETS1 oncogene contributes to human granulocytic differentiation. Haematologica, 2010, 95, 1633-1641.	3.5	20
67	Bone marrow-derived progenitors are greatly reduced in patients with severe COPD and low-BMI. Respiratory Physiology and Neurobiology, 2010, 170, 23-31.	1.6	47
68	TRAIL/TRAILâ€R in hematologic malignancies. Journal of Cellular Biochemistry, 2010, 110, 21-34.	2.6	40
69	Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors. International Journal of Oncology, 2010, 36, 707-13.	3.3	4
70	Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB Journal, 2010, 24, 1981-1988.	0.5	80
71	Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise. Journal of Applied Physiology, 2010, 109, 60-67.	2.5	58
72	Transferrin Receptor 2 Is Frequently and Highly Expressed in Glioblastomas. Translational Oncology, 2010, 3, 123-134.	3.7	106

#	Article	IF	Citations
73	The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells, Molecules, and Diseases, 2010, 45, 86-92.	1.4	133
74	Erythropoietic stimulating agents. Expert Opinion on Emerging Drugs, 2010, 15, 119-138.	2.4	15
75	Cells with Characteristics of Cancer Stem/Progenitor Cells Express the CD133 Antigen in Human Endometrial Tumors. Clinical Cancer Research, 2009, 15, 4299-4311.	7.0	153
76	Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Annals of Hematology, 2009, 88, 505-528.	1.8	55
77	Unilineage hematopoietic differentiation in bulk and single cell culture. Stem Cells, 2009, 16, 51-73.	3.2	16
78	Interleukin (IL)â€3/granulocyte macrophageâ€colony stimulating factor/ILâ€5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMSâ€related tyrosine kinase 3 receptor. British Journal of Haematology, 2009, 144, 376-387.	2.5	40
79	Colocalization of the VEGFâ€R2 and the common ILâ€3/GMâ€CSF receptor beta chain to lipid rafts leads to enhanced p38 activation. British Journal of Haematology, 2009, 145, 399-411.	2.5	19
80	A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene, 2009, 28, 4034-4040.	5.9	81
81	PLZF-mediated control on c-kit expression in CD34+ cells and early erythropoiesis. Oncogene, 2009, 28, 2276-2288.	5.9	24
82	MicroRNAs in normal and malignant myelopoiesis. Leukemia Research, 2009, 33, 1584-1593.	0.8	30
83	Discovery of a new family of bis-8-hydroxyquinoline substituted benzylamines with pro-apoptotic activity in cancer cells: Synthesis, structureâ€"activity relationship, and action mechanism studies. European Journal of Medicinal Chemistry, 2009, 44, 558-567.	5.5	46
84	High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide. Cancer Letters, 2009, 282, 214-228.	7.2	24
85	Regulation of transferrin receptor 2 in human cancer cell lines. Blood Cells, Molecules, and Diseases, 2009, 42, 5-13.	1.4	10
86	TfR2 expression in human colon carcinomas. Blood Cells, Molecules, and Diseases, 2009, 43, 243-249.	1.4	26
87	Triterpenoids as new promising anticancer drugs. Anti-Cancer Drugs, 2009, 20, 880-892.	1.4	309
88	Proteasome Inhibitors in Cancer Therapy. Current Drug Targets, 2009, 10, 968-981.	2.1	29
89	Role Of Stem Cell Factor In The Reactivation Of Human Fetal Hemoglobin. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009009.	1.3	4
90	Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels. Leukemia Research, 2008, 32, 1244-1258.	0.8	6

#	Article	IF	Citations
91	A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nature Cell Biology, 2008, 10, 788-801.	10.3	214
92	Effective erythropoiesis and HbF reactivation induced by kit ligand in Î²-thalassemia. Blood, 2008, 111, 421-429.	1.4	17
93	Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood, 2008, 112, 2450-2462.	1.4	73
94	Vascular endothelial growth factors in cardiovascular medicine. Journal of Cardiovascular Medicine, 2008, 9, 1190-1221.	1.5	73
95	Kit mutations in cancer and their treatment with protein kinase inhibitors. Drugs of the Future, 2008, 33, 0161.	0.1	3
96	Physiology of erythropoiesis. , 2008, , 1-66.		0
97	Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells, Molecules, and Diseases, 2007, 39, 82-91.	1.4	145
98	Deregulation of apoptosis in acute myeloid leukemia. Haematologica, 2007, 92, 81-94.	3.5	117
99	MicroRNAs 17-5pâ€“20aâ€“106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nature Cell Biology, 2007, 9, 775-787.	10.3	413
100	Î”N-p73 is a transcriptional target of the PML/RARÎ± oncogene in myeloid differentiation. Cell Death and Differentiation, 2007, 14, 1968-1971.	11.2	9
101	M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomibâ€mediated apoptosis. British Journal of Haematology, 2007, 139, 194-205.	2.5	36
102	Methylation damage response in hematopoietic progenitor cells. DNA Repair, 2007, 6, 1170-1178.	2.8	13
103	A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecologic Oncology, 2007, 105, 481-492.	1.4	35
104	Transferrin receptor 2 is emerging as a major player in the control of iron metabolism. Open Life Sciences, 2007, 2, 34-55.	1.4	3
105	Expression of Tie-2 and Other Receptors for Endothelial Growth Factors in Acute Myeloid Leukemias Is Associated with Monocytic Features of Leukemic Blasts. Stem Cells, 2007, 25, 1862-1871.	3.2	16
106	Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 635-655.	4.9	47
107	In vitro dual effect of arsenic trioxide on hemopoiesis: Inhibition of erythropoiesis and stimulation of megakaryocytic maturation. Blood Cells, Molecules, and Diseases, 2006, 36, 59-76.	1.4	9
108	Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells, Molecules, and Diseases, 2006, 37, 218-225.	1.4	22

#	Article	IF	Citations
109	Coordinate release of angiogenic growth factors after acute myocardial infarction: evidence of a two-wave production. Journal of Cardiovascular Medicine, 2006, 7, 872-879.	1.5	22
110	Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line. Cell Death and Differentiation, 2006, 13, 61-74.	11.2	24
111	Overexpression of Ets-1 in human hematopoietic progenitor cells blocks erythroid and promotes megakaryocytic differentiation. Cell Death and Differentiation, 2006, 13, 1064-1074.	11.2	47
112	Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes. Leukemia, 2006, 20, 1978-1988.	7.2	31
113	PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells. Oncogene, 2006, 25, 399-408.	5.9	14
114	Relation of Various Plasma Growth Factor Levels in Patients With Stable Angina Pectoris and Total Occlusion of a Coronary Artery to the Degree of Coronary Collaterals. American Journal of Cardiology, 2006, 97, 472-476.	1.6	17
115	Circulating CD34+ Cells Are Decreased in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 537-538.	3.5	7
116	Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. European Respiratory Journal, 2006, 27, 529-541.	6.7	180
117	Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. Journal of Cell Science, 2006, 119, 744-752.	2.0	58
118	TfR2 localizes in lipid raft domains and is released in exosomes to activate signal transduction along the MAPK pathway. Journal of Cell Science, 2006, 119, 4486-4498.	2.0	174
119	MicroRNAs 17-5p/20a/106a Function as a Master Gene Complex Controlling Monocytopoiesis through AML1 Targeting.. Blood, 2006, 108, 1186-1186.	1.4	0
120	Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood, 2005, 106, 2527-2529.	1.4	41
121	Supramaximal exercise mobilizes hematopoietic progenitors and reticulocytes in athletes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 289, R1496-R1503.	1.8	81
122	Multiple Members of the TNF Superfamily Contribute to IFN-Î³-Mediated Inhibition of Erythropoiesis. Journal of Immunology, 2005, 175, 1464-1472.	0.8	81
123	Role of IL-6 and CD23 in the resistance to growth arrest and apoptosis in LCL41 B lymphoma cells. Cytokine, 2005, 31, 314-323.	3.2	2
124	Apotosis-based therapies for hematological malignancies. Drugs of the Future, 2005, 30, 707.	0.1	1
125	TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica, 2005, 90, 612-24.	3.5	84
126	Immunophenotypic Features of Acute Myeloid Leukemias Overexpressing the Interleukin 3 Receptor Alpha Chain. Leukemia and Lymphoma, 2004, 45, 1511-1517.	1.3	17

#	Article	IF	Citations
127	Interleukin-3 receptor in acute leukemia. Leukemia, 2004, 18, 219-226.	7.2	109
128	Apoptotic mechanisms in the control of erythropoiesis. Leukemia, 2004, 18, 1176-1199.	7.2	205
129	Impaired myelopoiesis in mice devoid of interferon regulatory factor 1. Leukemia, 2004, 18, 1864-1871.	7.2	42
130	Analysis of p73 expression pattern in acute myeloid leukemias: lack of Î”N-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia, 2004, 18, 1804-1809.	7.2	24
131	Transferrin receptor 2 protein is not expressed in normal erythroid cells. Biochemical Journal, 2004, 381, 629-634.	3.7	23
132	Interferon regulatory factor-2 drives megakaryocytic differentiation. Biochemical Journal, 2004, 377, 367-378.	3.7	31
133	Interleukin-3 receptor as a target for antileukemic drugs. Drugs of the Future, 2004, 29, 821.	0.1	1
134	In vitro assays of tumor chemosensitivity and chemoresistance. Drugs of the Future, 2004, 29, 1035.	0.1	1
135	Control of erythroid cell production via caspase-mediated cleavage of transcription factor SCL/Tal-1. Cell Death and Differentiation, 2003, 10, 905-913.	11.2	45
136	Zinc modulates c-Myc/Mad1 balance in human leukemia cells. Leukemia, 2003, 17, 272-274.	7.2	1
137	C-fms expression correlates with monocytic differentiation in PML-RARÎ±+ acute promyelocytic leukemia. Leukemia, 2003, 17, 98-113.	7.2	16
138	Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. Blood, 2003, 102, 87-93.	1.4	51
139	HbF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with low-dose dexamethasone. Blood, 2003, 101, 2826-2832.	1.4	15
140	Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood, 2003, 101, 1316-1323.	1.4	141
141	Modulation by Growth Factors of the Expression of Interleukin 3 and Granulocyte-macrophage Colony-stimulating Factor Receptor Common Chain Î²c. Leukemia and Lymphoma, 2002, 43, 1645-1650.	1.3	3
142	Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors. Blood, 2002, 99, 4634-4637.	1.4	14
143	Elevated expression of IL-3RÎ± in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood, 2002, 100, 2980-2988.	1.4	272
144	Identification of the hemangioblast in postnatal life. Blood, 2002, 100, 3203-3208.	1.4	246

#	Article	IF	Citations
145	Platelet formation: a link between apoptosis and differentiation. Blood, 2002, 100, 1111-1112.	1.4	5
146	Role of Ets-1 in Erythroid Differentiation. Blood Cells, Molecules, and Diseases, 2002, 29, 553-561.	1.4	9
147	Circulating hematopoietic progenitor cells in runners. Journal of Applied Physiology, 2002, 93, 1691-1697.	2.5	98
148	Expression pattern of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia. Leukemia, 2002, 16, 1293-1301.	7.2	29
149	PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein. Oncogene, 2002, 21, 6669-6679.	5.9	46
150	Role of Ets-1 in transcriptional regulation of transferrin receptor and erythroid differentiation. Oncogene, 2002, 21, 7933-7944.	5.9	25
151	Recent developments in the understanding of iron metabolism. The Hematology Journal, 2002, 3, 63-89.	1.4	12
152	Ectopic expression of interferon regulatory factor-1 potentiates granulocytic differentiation. Biochemical Journal, 2001, 360, 285.	3.7	18
153	Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis. Biochemical Journal, 2001, 355, 587-595.	3.7	26
154	Ectopic expression of interferon regulatory factor-1 potentiates granulocytic differentiation. Biochemical Journal, 2001, 360, 285-294.	3.7	30
155	Stromal cellâ€“derived factor 1Î± increases polyploidization of megakaryocytes generated by human hematopoietic progenitor cells. Blood, 2001, 97, 2587-2595.	1.4	67
156	Polyclonal expansion of CD3⁺/CD4⁺/CD56⁺ large granular lymphocytes and autoimmunity associated with dysregulation of Fas/FasL apoptotic pathway. British Journal of Haematology, 2001, 112, 204-207.	2.5	10
157	Mechanisms of differential transferrin receptor expression in normal hematopoiesis. FEBS Journal, 2000, 267, 6762-6774.	0.2	39
158	Expression of interleukin 3 and granulocyteâ€“macrophage colonyâ€stimulating factor receptor common chain Î²c, Î²_{IT} in normal haematopoiesis: lineage specificity and proliferationâ€independent induction. British Journal of Haematology, 2000, 111, 441-451.	2.5	2
159	Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate. Blood, 2000, 95, 3555-3561.	1.4	54
160	Expression of interleukin 3 and granulocyte-macrophage colony-stimulating factor receptor common chain betac, betaIT in normal haematopoiesis: lineage specificity and proliferation-independent induction. British Journal of Haematology, 2000, 111, 441-451.	2.5	13
161	Mechanisms of differential transferrin receptor expression in normal hematopoiesis. FEBS Journal, 2000, 267, 6762-6774.	0.2	1
162	The Activity of the CCAAT-box Binding Factor NF-Y Is Modulated Through the Regulated Expression of Its A Subunit During Monocyte to Macrophage Differentiation: Regulation of Tissue-Specific Genes Through a Ubiquitous Transcription Factor. Blood, 1999, 93, 519-526.	1.4	75

#	Article	IF	Citations
163	IL-6, M-CSF and IAP Cytokines in Ovarian Cancer: Simultaneous Assessment of Serum Levels. Oncology, 1999, 57, 211-215.	1.9	27
164	STAT1 activation during monocyte to macrophage maturation: role of adhesion molecules. International Immunology, 1999, 11, 1075-1083.	4.0	68
165	Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature, 1999, 401, 489-493.	27.8	369
166	Expression and role of PML gene in normal adult hematopoiesis: functional interaction between PML and Rb proteins in erythropoiesis. Oncogene, 1999, 18, 3529-3540.	5.9	23
167	Transcriptional Regulation of the Ferritin H-Chain and Transferrin Receptor in Hematopoietic Cells. , 1999, , 391-402.		1
168	Terminal megakaryocytic differentiation of TF-1 cells is induced by phorbol esters and thrombopoietin and is blocked by expression of PML/RARÎ± fusion protein. Leukemia, 1998, 12, 563-570.	7.2	20
169	The synergistic effect of simultaneous addition of retinoic acid and vitamin D3 on the in-vitro differentiation of human promyelocytic leukemia cell lines could be efficiently transposed in vivo. Medical Hypotheses, 1998, 50, 253-257.	1.5	3
170	Oxidative Stress Leads to a Rapid Alteration of Transferrin Receptor Intravesicular Trafficking. Experimental Cell Research, 1998, 241, 102-116.	2.6	50
171	Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RARÎ± Protein in Acute Promyelocytic Leukemia Cells. Journal of the National Cancer Institute, 1998, 90, 124-133.	6.3	344
172	Secondary Leukemia Responsive to Retinoic Acid With Abnormal Localization of RARÎ± Protein: A Report of Two Cases. Blood, 1998, 91, 4811-4813.	1.4	4
173	The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.. Journal of Clinical Investigation, 1998, 101, 2278-2289.	8.2	25
174	Transcriptional Regulation of the Ferritin Heavy-Chain Gene: the Activity of the CCAAT Binding Factor NF-Y Is Modulated in Heme-Treated Friend Leukemia Cells and during Monocyte-to-Macrophage Differentiation. Molecular and Cellular Biology, 1997, 17, 1387-1395.	2.3	85
175	Opposite Effects of the Acute Promyelocytic Leukemia PML-Retinoic Acid Receptor Î± (RARÎ±) and PLZF-RARÎ± Fusion Proteins on Retinoic Acid Signalling. Molecular and Cellular Biology, 1997, 17, 4859-4869.	2.3	132
176	Autologous Stem Cell Transplantation: Exogenous Granulocyte Colony-Stimulating Factor or Granulocyte-Macrophage Colony-Stimulating Factor Modulate the Endogenous Cytokine Levels. Blood, 1997, 89, 2615-2617.	1.4	5
177	Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): possible role of lactoferrin and interleukin-1 receptor antagonist. Bone Marrow Transplantation, 1997, 20, 355-364.	2.4	26
178	Regulation of Expression of Ferritin H-chain and Transferrin Receptor by Protoporphyrin IX. FEBS Journal, 1997, 250, 764-772.	0.2	5
179	Interleukins 6 and 8 as Mediators of Acute Phase Response in Acute Myocardial Infarction. American Journal of Cardiology, 1997, 80, 622-625.	1.6	61
180	Autologous stem cell transplantation: evaluation of erythropoietic reconstitution by highly fluorescent reticulocyte counts, erythropoietin, soluble transferrin receptors, ferritin, TIBC and iron dosages. British Journal of Haematology, 1997, 96, 762-775.	2.5	16

#	Article	IF	Citations
181	Hypereosinophilia during 2â€chlorodeoxyadenosine treatment for hairy cell leukaemia. British Journal of Haematology, 1996, 92, 426-428.	2.5	17
182	Tumor necrosis factor Î± is a powerful apoptotic inducer in lymphoid leukemic cells expressing the P-170 glycoprotein. , 1996, 67, 238-247.		20
183	Iron Regulation of Transferrin Receptor and Ferritin Expression in Differentiating Friend Leukemia Cells. , 1996, , 693-703.		0
184	Modulation of retinoblastoma gene in normal adult hematopoiesis: peak expression and functional role in advanced erythroid differentiation.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 4808-4812.	7.1	52
185	Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. British Journal of Cancer, 1995, 71, 354-356.	6.4	174
186	Cytokine regulation of astrocyte function:in-vitrostudies using cells from the human brain. International Journal of Developmental Neuroscience, 1995, 13, 265-274.	1.6	67
187	Differential expression and functional role of GATA-2, NF-E2, and GATA-1 in normal adult hematopoiesis.. Journal of Clinical Investigation, 1995, 95, 2346-2358.	8.2	115
188	High Dose-Intense Chemotherapy Alone or in Combination with Interleukin-2 for Small Cell Lung Cancer: A Pilot Study. Cancer Investigation, 1994, 12, 574-587.	1.3	5
189	Interleukin-6 serum levels in patients with gynecological tumors. International Journal of Cancer, 1994, 57, 318-323.	5.1	89
190	Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. American Journal of Cardiology, 1994, 74, 468-473.	1.6	132
191	gp120 HIV envelope glycoprotein increases the production of nitric oxide in human monocyte-derived macrophages. Journal of Leukocyte Biology, 1994, 55, 175-182.	3.3	114
192	Oxidative stress and transferrin receptor recycling. Cytotechnology, 1993, 11, S53-S55.	1.6	1
193	Mannoprotein-Induced Anti-U937 Cell Cytotoxicity in Peripheral Blood Mononuclear Cells from Uninfected or HIV-Infected Subjects: Role of Interferon-Î³ and Tumor Necrosis Factor-Î±. Cellular Immunology, 1993, 152, 530-543.	3.0	6
194	The acute promyelocytic leukemia-specific PML-RARÎ± fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell, 1993, 74, 423-431.	28.9	583
195	Post-transcriptional regulation of transferrin receptor mRNA by IFNÎ³. Nucleic Acids Research, 1992, 20, 2997-3003.	14.5	24
196	Extrachromosomal human immunodeficiency virus type 1 DNA forms in fresh peripheral blood lymphocytes and in two interleukin-2-independent T cell lines derived from peripheral blood lymphocytes of an asymptomatic seropositive subject. Journal of General Virology, 1992, 73, 3087-3097.	2.9	11
197	Transferrin receptor mediates uptake and presentation of hepatitis B envelope antigen by T lymphocytes.. Journal of Experimental Medicine, 1992, 175, 1195-1205.	8.5	101
198	Cell cycle-dependent initiation and lineage-dependent abrogation of GATA-1 expression in pure differentiating hematopoietic progenitors.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6353-6357.	7.1	149

#	Article	IF	Citations
199	Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: Role of cell adhesion to endothelium. European Journal of Cancer, 1992, 28, 818-825.	2.8	24
200	PCR analysis of HIV-1 sequences and differential immunological features in seronegative and seropositive haemophiliacs. British Journal of Haematology, 1992, 81, 558-567.	2.5	3
201	Astrocyte cultures from human embryonic brain: Characterization and modulation of surface molecules by inflammatory cytokines. Journal of Neuroscience Research, 1992, 32, 494-506.	2.9	128
202	Pure Human Hematopoietic Progenitors: Direct Inhibitory Effect of Transforming Growth Factors-?1 and -?2. Annals of the New York Academy of Sciences, 1991, 628, 84-91.	3.8	17
203	Molecular heterogeneity of the 1.0-kb TÎ² transcript in natural killer and Î³/Î´ lymphocytes. European Journal of Immunology, 1991, 21, 1529-1534.	2.9	5
204	IL-2 induces the release of secondary cytokines which stimulate the cytotoxic activity of either NK or CD8+ lymphocytes. Cytotechnology, 1991, 5, 126-129.	1.6	0
205	Long-term culture of human LAK cells. Cytotechnology, 1991, 5, 139-140.	1.6	0
206	Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.. Journal of Experimental Medicine, 1991, 173, 313-322.	8.5	35
207	Reactivation of HbF synthesis in normal adult erythroid bursts by IL-3. British Journal of Haematology, 1990, 74, 114-117.	2.5	15
208	Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, TiÎ³/Î´ or TNK phenotype. Cancer Immunology, Immunotherapy, 1990, 31, 11-18.	4.2	9
209	Natural killer cells carry the germ-line configuration of the T cell receptor Î´ chain gene and heterogeneously express six distinct Î´ transcripts. European Journal of Immunology, 1990, 20, 939-942.	2.9	7
210	Molecular mechanisms underlying the expression of the human HOX-5.1 gene. Nucleic Acids Research, 1990, 18, 4361-4368.	14.5	50
211	"Pure" human hematopoietic progenitors: permissive action of basic fibroblast growth factor. Science, 1990, 249, 1561-1564.	12.6	234
212	Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. European Journal of Cancer & Clinical Oncology, 1990, 26, 1152-1156.	0.7	56
213	Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. International Journal of Cancer, 1989, 44, 1108-1116.	5.1	37
214	Three new class I HLA alleles: structure of mRNAs and alternative mechanisms of processing. Immunogenetics, 1989, 29, 80-91.	2.4	42
215	Interferons and the Differentiation of Friend Cells. Annals of the New York Academy of Sciences, 1989, 567, 253-258.	3.8	1
216	TGF Î² induces a sustained c-fos expression associated with stimulation or inhibition of cell growth in EL2 or NIH 3T3 fibroblasts. Biochemical and Biophysical Research Communications, 1988, 151, 298-305.	2.1	21

#	Article	IF	Citations
217	Human platelet alpha granules contain a nonspecific inhibitor of megakaryocyte colony formation: Its relationship to type ? transforming growth factor (TGF-?). Journal of Cellular Physiology, 1988, 134, 93-100.	4.1	87
218	Differential Regulation of Transferrin Receptor Gene Expression in Human Hemopoietic Cells: Molecular and Cellular Aspects. Journal of Receptors and Signal Transduction, 1987, 7, 355-375.	1.2	5
219	Expression of Transferrin Receptors: Differential Regulatory Mechanisms in Monocytes-macrophages versus Other Hemopoietic Cells. Annals of the New York Academy of Sciences, 1987, 511, 131-137.	3.8	3
220	Expression and In-vitro Modulation of HLA Antigens in Ontogenic Development of Human Hemopoietic System. Annals of the New York Academy of Sciences, 1987, 511, 138-147.	3.8	8
221	Expression of c-fos in Human Normal and Neoplastic Monocyte-Macrophage Differentiation. Annals of the New York Academy of Sciences, 1987, 511, 277-283.	3.8	1
222	The EL2 Rat Fibroblasts Line: Differential Effects of Growth Factors (EGF, PDGF, FGF, TPA and TGF?) on Cell Proliferation and c-fos Expression. Annals of the New York Academy of Sciences, 1987, 511, 318-328.	3.8	15
223	Specific modulation of surface receptors in J.774 macrophages by anchorage. Experimental Cell Research, 1987, 170, 290-299.	2.6	8
224	Neonatal jaundice and severity of glucose-6-phosphate dehydrogenase deficiency in Sardinian babies. Early Human Development, 1987, 15, 317-322.	1.8	31
225	HLA antigens on human hemopoietic progenitors during embryonic-fetal life: Expression and in vitro modulation. Cell Biology International Reports, 1986, 10, 775-788.	0.6	3
226	Human embryonic hemopoiesis. Kinetics of progenitors and precursors underlying the yolk sac---liver transition.. Journal of Clinical Investigation, 1986, 78, 51-60.	8.2	265
227	Induction of (2â€²â€“5â€²) oligoadenylate synthetase activity during granulocyte and monocyte differentiation. Molecular and Cellular Biochemistry, 1985, 67, 125-133.	3.1	19
228	The iron-chelating agent picolinic acid enhances transferrin receptors expression in human erythroleukaemic cell lines. British Journal of Haematology, 1985, 60, 491-502.	2.5	28
229	Inhibition of insulin receptor binding by A23187: Synergy with phorbol esters. Biochemical and Biophysical Research Communications, 1985, 130, 9-15.	2.1	4
230	Differentiation of U-937 human monocyte-like cell line by 1Î±,25-dihydroxyvitamin D3 or by retinoic acid. Experimental Cell Research, 1985, 157, 539-543.	2.6	12
231	Molecular mechanisms regulating the synthesis of transferrin receptors and ferritin in human erythroleukemic cell lines. FEBS Letters, 1985, 183, 223-227.	2.8	13
232	Presence of the Tn antigen on hematopoietic progenitors from patients with the Tn syndrome.. Journal of Clinical Investigation, 1985, 75, 541-546.	8.2	27
233	K562 cells induced to differentiate by phorbol ester tumor promotors resist NK lysis. Cellular Immunology, 1984, 87, 389-399.	3.0	19
234	Inhibition of transferrin binding and iron uptake of hematopoietic cell lines by phorbol esters. Leukemia Research, 1984, 8, 597-609.	0.8	13

#	Article	IF	Citations
235	Defect in glycosylation of erythrocyte membrane proteins in congenital dyserythropoietic anaemia type II (HEMPAS). British Journal of Haematology, 1984, 56, 55-68.	2.5	60
236	Expression of SSEA-I antigen (3-fucosyl-N-acetyl-lactosamine) on normal and leukaemic human haemopoietic cells: modulation by neuraminidase treatment. British Journal of Haematology, 1984, 58, 697-710.	2.5	22
237	The role of iron in the growth of human leukemic cell lines. Journal of Cellular Physiology, 1984, 121, 251-256.	4.1	45
238	Phorbol esters inhibit the binding of low-density lipoproteins (LDL) to U-937 monocytelike cells. Journal of Cellular Physiology, 1984, 121, 540-546.	4.1	23
239	Target structure for natural killer cells: evidence against a unique role for transferrin receptor. European Journal of Immunology, 1984, 14, 340-344.	2.9	30
240	Expression of an accessory cell phenotype by hairy cells during lymphocyte colony formation in agar culture. Leukemia Research, 1983, 7, 87-95.	0.8	6
241	The origin of human B and T cells from multipotent stem cells: a study of the Tn syndrome. European Journal of Immunology, 1983, 13, 350-352.	2.9	27
242	Erythroid properties of K562 cells. Experimental Cell Research, 1983, 146, 428-435.	2.6	54
243	Transferrin binding to K562 cell line *1Effect of heme and sodium butyrate induction. Experimental Cell Research, 1982, 140, 251-260.	2.6	63
244	Hemin regulates the expression of transferrin receptors in human hematopoietic cell lines. FEBS Letters, 1982, 145, 350-354.	2.8	50
245	Hemoglobin Expression in Clones of K562 Cell Line. FEBS Journal, 1982, 121, 649-655.	0.2	20
246	Inhibition of Insulin Receptor Binding by Phorbol Esters. FEBS Journal, 1982, 129, 389-393.	0.2	102
247	Hb Switching in neonatal cultures. Increase of Hb A synthesis in presence of an erythroid potentiating activity (EPA). Journal of Cellular Physiology, 1982, 110, 196-202.	4.1	4
248	Clonal Expression of the Tn Antigen in Erythroid and Granulocyte Colonies and Its Application to Determination of the Clonality of the Human Megakaryocyte Colony Assay. Journal of Clinical Investigation, 1982, 69, 1081-1091.	8.2	46
249	New genetic variants of glucose 6-phosphate dehydrogenase (G6PD) in Italy. Annals of Human Genetics, 1981, 45, 97-104.	0.8	5
250	Change in i-antigen expression of erythrocytes during in vivo aging. Revue FranÃ§aise De Transfusion Et Immuno-hÃ©matologie, 1981, 24, 299-305.	0.1	6
251	Genetic regulation of ? gene expression: Study of the interaction of ?-thalassemia with heterocellular HPFH. Human Genetics, 1981, 57, 371-375.	3.8	10
252	Comparative patterns of i-antigen expression, F-cell frequency and Hb A2 level in acute myeloid leukemia and in acute lymphoid leukemia. Leukemia Research, 1981, 5, 203-213.	0.8	0

#	Article	IF	Citations
253	RECEPTORS FOR INSULIN-LIKE PEPTIDES (ILAs) IN RAT RETICULOCYTES AND ERYTHROCYTES.. Endocrinology, 1981, 108, 1087-1090.	2.8	13
254	Hemoglobin Synthesis in 7-Day and 14-Day-Old Erythroid Colonies from the Bone Marrow of Normal Individuals. Hemoglobin, 1980, 4, 53-67.	0.8	14
255	Fetal hemoglobin synthesis in culture of early erythroid precursors (BFU-E) from the blood of normal adults. Journal of Cellular Physiology, 1980, 102, 297-303.	4.1	6
256	Disappearance of Hb F and i antigen during the first year of life. American Journal of Hematology, 1980, 9, 161-170.	4.1	15
257	Globinâ€Chain Affinity Chromatography on Sepharoseâ€Haptoglobin a New Method of Study of Hemoglobin Synthesis in Reticulocytes, in Bone Marrow and in Colonies of Erythroid Precursors. FEBS Journal, 1980, 112, 513-519.	0.2	16
258	Insulin receptors and protein synthesis in bone marrow cells and reticulocytes. Diabetes, 1980, 29, 820-824.	0.6	11
259	Fetal to adult hemoglobin switch in cultures of early erythroid precursors from human fetuses and neonates. American Journal of Hematology, 1979, 7, 207-218.	4.1	19
260	Genetic heterogeneity of "normal" human erythrocyte glucose-6-phosphate dehydrogenase: an isoelectrophoretic polymorphism.. Proceedings of the National Academy of Sciences of the United States of America, 1979, 76, 852-856.	7.1	30